Vor Bio (NASDAQ: VOR) announced it has entered into a securities purchase agreement to sell 5,338,078 shares of common stock at $14.05 per share in a private placement expected to generate approximately $75 million in gross proceeds.

The financing is led by new investor TCGX, a healthcare investment firm. The private placement is expected to close on or about March 30, 2026, subject to customary closing conditions. Vor Bio did not engage a placement agent for the transaction.

The company plans to use the net proceeds to advance clinical development of telitacicept, including ongoing global Phase 3 clinical trials for myasthenia gravis and primary Sjögren's disease, as well as for business development, working capital and general corporate purposes.

"BAFF/APRIL inhibition represents one of the next major waves of innovation in autoimmune disease, and telitacicept is at the forefront of the field," said Jean-Paul Kress, Chief Executive Officer and Chairman of Vor Bio. The company aims to accelerate efforts in generalized myasthenia gravis and advance primary Sjögren's disease development.

"Our investment reflects the conviction we have in the Vor Bio team and the disruptive potential of telitacicept," said Cariad Chester, Managing Partner at TCGX.

Vor Bio is a clinical-stage biotechnology company focused on advancing telitacicept, described as a dual-target fusion protein for autoantibody-driven conditions. The securities have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States without registration or applicable exemption.

The company has agreed to file a registration statement with the Securities and Exchange Commission for the resale of shares issued in the private placement, according to the press release.